Theta Burst Stimulation for Tourette Syndrome
Trial Summary
What is the purpose of this trial?
This trial uses a non-invasive magnetic pulse therapy to help Tourette Syndrome patients by improving their brain's ability to control movements and reduce tics. This therapy has shown promising results in reducing tic severity in Tourette Syndrome.
Do I need to stop my current medications for the trial?
The trial protocol does not specify if you need to stop your current medications. However, you must not have changed your psychotropic medications or increased their dosage in the last 14 days before starting the TMS treatment.
What data supports the idea that Theta Burst Stimulation for Tourette Syndrome is an effective treatment?
The available research shows that Theta Burst Stimulation (TBS) has been used to treat conditions like tinnitus, which is a persistent ringing in the ears, often linked with depression. In one case, a woman's tinnitus intensity decreased significantly after TBS treatment, and her depression symptoms also improved. However, the research does not provide specific data on TBS for Tourette Syndrome. Therefore, while TBS shows promise for other conditions, more research is needed to confirm its effectiveness for Tourette Syndrome.12345
What safety data exists for Theta Burst Stimulation in treating Tourette Syndrome?
The provided research does not contain specific safety data for Theta Burst Stimulation (iTBS) in treating Tourette Syndrome. The studies focus on other treatments like Deep Brain Stimulation (DBS) and medications such as valbenazine and aripiprazole. To find safety data for iTBS, further research specifically targeting this treatment would be necessary.678910
Is iTBS a promising treatment for Tourette Syndrome?
iTBS, or Intermittent Theta Burst Stimulation, is a promising treatment because it has shown positive effects in improving motor functions and mood in other conditions like Parkinson's disease, multiple sclerosis, and depression. It is a newer form of therapy that can be delivered quickly and has been effective in helping patients with treatment-resistant depression.1112131415
Research Team
Eligibility Criteria
This trial is for young people aged 10-21 with Tourette Syndrome (TS) who speak English and can understand the study. They should be clinically stable, meaning no recent changes in their psychotropic medications or other therapies. Participants must not have any metal in their body or certain psychiatric conditions beyond TS, ADHD, OCD, or mild anxiety.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- iTBS (Non-invasive Brain Stimulation)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Children's Hospital Medical Center, Cincinnati
Lead Sponsor
Steve Davis
Children's Hospital Medical Center, Cincinnati
Chief Executive Officer since 2021
MD
Daniel Ostlie
Children's Hospital Medical Center, Cincinnati
Chief Medical Officer
MD from University of North Dakota
Tourette Association of America
Collaborator